Modality
mRNA
MOA
GLP-1ag
Target
PLK4
Pathway
Tau
DravetCholangiocarcinomaNSCLC
Development Pipeline
Preclinical
~Dec 2023
→ ~Mar 2025
Phase 1
Jun 2025
→ Mar 2030
Phase 1Current
NCT04053110
1,543 pts·NSCLC
2025-07→2030-03·Active
NCT03741438
949 pts·NSCLC
2025-06→2029-11·Completed
2,492 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-11-063.6y awayInterim· NSCLC
2030-03-154.0y awayInterim· NSCLC
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Complet…
P1
Active
Catalysts
Interim
2029-11-06 · 3.6y away
NSCLC
Interim
2030-03-15 · 4.0y away
NSCLC
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |